[
    [
        {
            "time": "",
            "original_text": "【民生医药|点评】康泰生物：销售费用增加影响利润，血制品将处于景气度持续上升趋势",
            "features": {
                "keywords": [
                    "康泰生物",
                    "销售费用",
                    "利润",
                    "血制品",
                    "景气度"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【民生医药|点评】康泰生物：销售费用增加影响利润，血制品将处于景气度持续上升趋势",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【民生医药|点评】康泰生物：Q1受疫情影响业绩大幅下滑，在研产品进入收获期 盈利能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "疫情",
                    "业绩",
                    "在研产品",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【民生医药|点评】康泰生物：Q1受疫情影响业绩大幅下滑，在研产品进入收获期 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "一季度机构扎堆医药消费科技龙头股",
            "features": {
                "keywords": [
                    "一季度",
                    "机构",
                    "医药",
                    "消费",
                    "科技",
                    "龙头股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "消费",
                    "科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "一季度机构扎堆医药消费科技龙头股",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【光大医药|年报＆Q1点评】康泰生物：Q1为全年业绩低点，四联苗批签发情况良好",
            "features": {
                "keywords": [
                    "康泰生物",
                    "年报",
                    "Q1",
                    "业绩",
                    "四联苗",
                    "批签发"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【光大医药|年报＆Q1点评】康泰生物：Q1为全年业绩低点，四联苗批签发情况良好",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]